

Tetsuya Mitsudomi, M.D., Ph. D.

Kinki University



- 1980 M.D. Kyushu University, School of Medicine, Japan
1986 Ph.D., Kyushu University, Graduate School of Medical Science.
1986-1988 Department of Surgery, Matsuyama Red Cross Hospital
1988-1989 Instructor, Department of Surgery II, Kyushu University
1989-1991 Postdoctoral Fellow, NCI-Navy Medical Oncology Branch, National Cancer Institute, National Institute of Health
1991-1994 Assistant professor, Department of Surgery II, University of Occupational and Environmental Health, Japan
1994-1995 Assistant professor, Department of Surgery II, Kyushu University
1995-2012 Chief, Department of Thoracic Surgery, Aichi Cancer Center Hospital
2012-present Professor, Department of Surgery, Kinki University Faculty of Medicine

Specialty and Research Field of Interest

Thoracic Surgery, Molecular Biology of Lung Cancer, Molecular Targeted Therapy

Selected Publications

1. Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T: The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. **Int J Cancer** 135:1002-6, 2014
2. Suda K, Mizuuchi H, Murakami I, Uramoto H, Tanaka F, Sato K, Takemoto T, Iwasaki T, Sekido Y, Yatabe Y, Mitsudomi T: CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. **Lung Cancer** 85:147-51, 2014
3. Mitsudomi T, Suda K, Yatabe Y: Surgery for NSCLC in the era of personalized medicine. **Nat Rev Clin Oncol** 10:235-44, 2013
4. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T: Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. **Lung Cancer** 77:319-25, 2012
5. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T: Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib. **J Thorac Oncol** 6:1152-1161, 2011
6. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T: Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. **Clin Cancer Res** 16:5489-98, 2010
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. **Lancet Oncol** 11:121-128, 2010